Together, these data suggest that HGF/c-Met pathway inhibition may overcome resistance to anti-EGFR therapy in R/M HNSCC, such as in patients with clinical cetuximab resistance. This evidence concerns the gene HGF and head and neck squamous cell carcinoma.